Immunotherapy

The second edition of __Immunotherapy__ is an updated overview of immuno-oncology in acute myleloid leukemia, non-small cell lung cancer and sarcomas, showcasing advances in the management of cancer broadly classified as hematological malignancies, solid tumors and tumors arising in the connective tissue. Scientists, oncologists and advanced students will be provided with knowledge of basic immunology in the context of tumor biology, providing a comprehensive overview of the cellular components of the immune system that interact with each other to provide a successful immune response. A number of new, scientific findings in his fast moving field have necessitated a thoroughly updated and revised edition including the use of immunotherapy for gastrointestinal and genitourinary cancers, as well as discussions on optimizing radiotherapy with immunotherapeutic approaches, biomarkers of response or resistance to immunotherapy, cancer imaging in immunotherapy, skin reactions to immune checkpoint inhibitors and more. As immunotherapeutic agents differ significantly from chemotherapeutic agents in response patterns and toxicity profiles, evaluating their safety and efficacy in clinical trials remains a challenge. The new edition will discuss the use of a variety of traditional and new immunotherapy criteria to evaluate response, their inadequacies and clinical implications. Additionally, the book will outline how new advances in medical imaging technology has the potential to provide high-dimensional data to improve decision support and individualize treatment selection and monitoring. Edited by two renowned experts in the field, the book’s chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science. The second edition of Immunotherapy is an updated overview of immuno-oncology in acute myleloid leukemia, non-small cell lung cancer and melanoma, showcasing advances in the management of cancer broadly classified as hematological malignancies and solid tumors. Though the spectrum of clinical activity and duration of response seen with these agents is promising, objective response is limited to a subset of patients and is often associated with distinct side effects that are potentially life-threatening. With increasing use of checkpoint inhibitors as standard of care and in clinical trials, the burden of immune-related adverse events will undoubtedly increase. Given these limitations and increase in health care costs associated with such therapies, it is essential to identify patients who are likely to respond to immunotherapy and those who are at a risk for developing treatment-related side effects. This new edition will inform readers on the latest in biomarker development to identify patients who are more likely to respond, and strategies to overcome the challenges of immune-related adverse events. In addition, the authors recognize that including the missing patient voice in clinical trials and longitudinal assessment of symptom reports may help to identify early indicators of response or toxicity. Thus, the book includes a chapter on patient-reported outcomes in patients treated with immunotherapies. The authors believe that acquiring this knowledge will help health care professionals make informed treatment decisions. Edited by two renowned experts in the field, the book's chapters are written by a diverse cast of experts conducting cutting-edge research, providing the reader with the most up-to-date science. Front Matter ....Pages i-viii Overview of Basic Immunology and Translational Relevance for Clinical Investigators (Bettzy Stephen, Joud Hajjar)....Pages 1-41 Immunotherapy for Melanoma (Isabella C. Glitza Oliva, Rana Alqusairi)....Pages 43-63 Immunotherapy in Lung Cancer: A New Age in Cancer Treatment (Luis Corrales, Katherine Scilla, Christian Caglevic, Ken Miller, Julio Oliveira, Christian Rolfo)....Pages 65-95 Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice (Lucia Masarova, Hagop Kantarjian, Farhad Ravandi, Padmanee Sharma, Guillermo Garcia-Manero, Naval Daver)....Pages 97-116 Skin Reactions to Immune Checkpoint Inhibitors (Anisha B. Patel, Omar Pacha)....Pages 117-129 Immune-Related Adverse Events: Pneumonitis (Akash Jain, Vickie R. Shannon, Ajay Sheshadri)....Pages 131-149 Immune Checkpoint Inhibitors-Induced Colitis (Yun Tian, Hamzah Abu-Sbeih, Yinghong Wang)....Pages 151-157 Immune Checkpoint Inhibitors-Induced Hepatitis (Yun Tian, Hamzah Abu-Sbeih, Yinghong Wang)....Pages 159-164 Symptoms as Patient-Reported Outcomes in Cancer Patients Undergoing Immunotherapies (Tito R. Mendoza)....Pages 165-182